Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (PRLD) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2020 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
PRLD on Nasdaq
Shares outstanding
51,297,696
Price per share
$2.15
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
28,458,620
Total reported value
$82,524,231
% of total 13F portfolios
0%
Share change
+1,310,489
Value change
+$4,105,993
Number of holders
47
Price from insider filings
$2.15
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (PRLD) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BAKER BROS. ADVISORS LP 24% $8,010,575 10,269,968 Baker Bros. Advisors LP 12 Jun 2025
Vaddi Krishna 13% -4.6% $19,562,376 +$1,008,643 6,745,647 +5.4% Vaddi Krishna 31 Dec 2025
INCYTE CORP 9.9% $6,295,859 4,372,124 INCYTE CORP 03 Nov 2025

As of 31 Dec 2025, 47 institutional investors reported holding 28,458,620 shares of Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (PRLD). This represents 55% of the company’s total 51,297,696 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (PRLD) together control 55% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
ORBIMED ADVISORS LLC 21% 10,909,256 0% 0.68% $31,636,842
BAKER BROS. ADVISORS LP 20% 10,123,824 0% 0.17% $29,359,090
VANGUARD GROUP INC 2.8% 1,413,986 +42% 0% $4,100,559
Kynam Capital Management, LP 1.5% 788,867 0.15% $2,287,714
TWO SIGMA INVESTMENTS, LP 1.5% 788,695 +418% 0% $2,287,216
PRICE T ROWE ASSOCIATES INC /MD/ 1.5% 755,956 -14% 0% $2,193,000
ACADIAN ASSET MANAGEMENT LLC 1% 535,703 -0.9% 0% $1,551,000
MORGAN STANLEY 0.65% 334,916 +18% 0% $971,257
MARSHALL WACE, LLP 0.53% 273,883 0% $794,260
GEODE CAPITAL MANAGEMENT, LLC 0.53% 272,886 +25% 0% $791,502
RENAISSANCE TECHNOLOGIES LLC 0.53% 271,300 -50% 0% $786,770
BlackRock, Inc. 0.52% 266,280 +0.49% 0% $772,212
TWO SIGMA ADVISERS, LP 0.46% 237,300 +6.6% 0% $688,170
TD Asset Management Inc 0.31% 160,652 0% 0% $465,891
MILLENNIUM MANAGEMENT LLC 0.29% 150,997 -87% 0% $437,891
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.26% 135,909 0% $394,136
STATE STREET CORP 0.25% 127,292 +30% 0% $369,147
SPHERA FUNDS MANAGEMENT LTD. 0.24% 122,752 0.07% $355,981
GOLDMAN SACHS GROUP INC 0.23% 117,477 +48% 0% $340,683
JANE STREET GROUP, LLC 0.22% 111,040 +219% 0% $322,016
OMERS ADMINISTRATION Corp 0.14% 73,000 0% $211,700
MANUFACTURERS LIFE INSURANCE COMPANY, THE 0.14% 70,546 +1.9% 0% $200,428
Point72 Asset Management, L.P. 0.12% 59,168 0% $171,587
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.1% 53,500 0% 0% $155,150
XTX Topco Ltd 0.1% 50,159 +222% 0% $145,461

Institutional Holders of Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (PRLD) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 28,458,620 $82,524,231 +$4,105,993 $2.90 47
2025 Q3 27,161,835 $39,111,943 +$249,044 $1.44 45
2025 Q2 27,187,955 $21,995,839 -$2,401,932 $0.81 49
2025 Q1 30,289,302 $23,267,043 -$2,260,767 $0.77 56
2024 Q4 32,136,788 $40,964,573 -$12,964,360 $1.28 60
2024 Q3 35,754,682 $74,021,916 +$3,111,676 $2.07 69
2024 Q2 33,917,161 $129,220,239 -$1,353,555 $3.81 59
2024 Q1 34,197,005 $162,095,049 -$2,346,403 $4.74 56
2023 Q4 34,725,223 $148,268,893 -$6,317,081 $4.27 55
2023 Q3 36,614,209 $113,138,241 +$1,036,814 $3.09 57
2023 Q2 36,273,689 $163,232,997 +$31,250,061 $4.50 52
2023 Q1 31,510,272 $179,609,477 +$1,734,926 $5.70 54
2022 Q4 31,178,634 $188,300,136 -$4,385,760 $6.04 59
2022 Q3 31,821,580 $210,332,653 -$5,208,246 $6.61 50
2022 Q2 32,736,159 $170,877,689 -$7,216,025 $5.22 55
2022 Q1 34,109,145 $235,382,986 -$10,995,652 $6.90 64
2021 Q4 35,151,511 $437,636,391 -$26,977,029 $12.45 74
2021 Q3 35,967,344 $1,123,981,157 +$47,268,239 $31.25 61
2021 Q2 34,458,535 $986,644,054 +$52,903,899 $28.63 56
2021 Q1 32,543,650 $1,410,113,760 -$96,898,538 $43.33 60
2020 Q4 34,651,491 $2,474,382,581 +$136,089,518 $71.55 51
2020 Q3 33,322,061 $999,836,330 +$999,836,330 $30.13 38